A new study conducted at the Dana-Farber Cancer Institute in Boston indicates that statins, used to lower cholesterol levels, "may slow the progression of prostate cancer in patients receiving hormone therapy." According to study senior author Dr. Philip Kantoff, chief of solid tumor oncology at Dana-Farber, this study, applicable only with advanced prostate cancer that has relapsed after hormone therapy, resulted in the cancer remaining stable for a longer time period (27.5 months compared to 17.4 months) for those taking statins.
To read more abut this study, click here.
No comments:
Post a Comment